Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real ChemistryHealthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real Chemistry

Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points

Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action

NEW YORK–(BUSINESS WIRE)–Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offers a new end-to-end model of healthcare advisory informed by deep expertise and real-time insights to deliver communication strategies and execution that drive desired outcomes.

“The healthcare industry is at a critical juncture, with the pace, complexity and consequences of decision-making accelerating rapidly,” said Jennifer Gottlieb, Global President and Head of Integrated Communications at Real Chemistry. “Healthcare leaders today are seeking highly specialized partners that combine deep industry expertise with advisory capabilities to navigate the regulatory shifts, reputational risk and financial uncertainties of the operating environment that make advancing business and science more complicated, more risky and potentially more costly. RC Resolve was created to meet this need, building on Real Chemistry’s 25-year legacy as a leading data-driven healthcare partner – bringing together seasoned industry leaders who have walked in our clients’ shoes and have decades of experience to help organizations move forward with clarity, confidence and decisive action.”

RC Resolve leverages proprietary, AI-powered intelligence, including ReputAI, an advanced reputation measurement and predictive message-testing suite, and HealthGEO, which assesses how large language models influence corporate perception to drive message clarity and measurable impact. Backed by Real Chemistry’s 2,000+ experts across life sciences, marketing communications and technology, RC Resolve provides healthcare advisory counsel – combining deep sector perspective with strategic foresight – to help organizations navigate complexity, strengthen trust and stay ahead of change.

RC Resolve’s advisory practice spans critical areas that meet clients’ most pressing communication needs, including:

  • Policy, Public Affairs and Access
  • Issues, Crisis and Risk Management
  • Transformation and Change Management
  • Executive Communications
  • Corporate Strategy and Reputation
  • Financial and Transaction Communications

RC Resolve’s Seasoned Senior A-Team

“RC Resolve was built specifically to bring together senior health advisors who understand the pressures from the outside in and can help leaders make confident, enterprise-level decisions with speed and precision – when it matters most,” said Sherry Pudloski, Group President of RC Resolve and Corporate Affairs at Real Chemistry. Pudloski previously served as chief communications and corporate affairs officer at Seagen, Zoetis and Guardian Life and held senior communications and strategy roles at Pfizer and Novartis.

RC Resolve comprises veterans with more than 20 years of experience advising leaders in the boardroom, newsroom, crisis room and policy environment, including:

  • Bridget Walsh, Head of Policy, Public Affairs and Access, held government affairs and policy leadership roles at Pfizer and Boehringer Ingelheim, including 10 years on Capitol Hill as a senior staffer to U.S. Senators.
  • Margaret (Maggie) Farley, Head of Issues, Crisis and Risk Management, is a renowned counselor across biopharmaceutical and medical device communications who led health crises and issues management at Edelman for two decades.
  • Amy Atwood, Head of Transformation and Change Management, brings deep experience leading corporate communications, change management and strategic transformation across global healthcare enterprises, most recently as Vice President, U.S. and Global Corporate Communications at Takeda.
  • Shoreen Maghame, Head of Executive Communications, is a strategic communications advisor to C-suite executives on global launches, crises and reputation management whose early career experience as an on-air journalist informs her practical, media-savvy approach to executive communications.
  • Piper Evans, Head of Corporate Strategy and Reputation, advises executives across academic medicine, integrated delivery systems, emerging biotechs and global health organizations. She joins from FGS Global and previously held positions at McKinsey & Company, Purple Strategies and the Public Affairs Council.
  • Leslie Isenegger, Head of Client Development, has industry-leading policy and pricing expertise and was most recently head of Real Chemistry’s Corporate Pricing and Public Affairs practice. She previously held positions at the Centers for Medicare & Medicaid Services (CMS) and the Greater New York Hospital Association.

RC Resolve’s Healthcare Advisory Council

Backing up the RC Resolve A-Team is a Healthcare Advisory Council of senior leaders with deep experience across regulatory, legal, health economics, healthcare financing and corporate affairs who will provide enterprise-level perspective and strategic decision-making.

Current members include Jim Weiss, Founder and Chairman of Real Chemistry; Shankar Narayanan, Chief Executive Officer (CEO) at Real Chemistry and former Partner, McKinsey & Company; Kirsten Axelsen, health economics expert and Senior Policy Advisor at DLA Piper; Murphy Gallagher, Senior Managing Director at Leerink Partners; Erica Jefferson, former Associate Commissioner for External Affairs at the U.S. Food and Drug Administration (FDA); and Alan Minsk, Partner and Co-Chair of the Food and Drug Practice team at Arnall Golden Gregory LLP. The membership of RC Resolve’s Healthcare Advisory Council will evolve alongside the healthcare and policy landscape, ensuring access to relevant expertise as novel issues and opportunities emerge.

“As a privately held company focused exclusively on healthcare, we’ve stayed true to our commitment to invest where it matters most for our clients’ growth,” said Narayanan. “Building on our strong momentum in 2025 – including expansion of our omni-first precision marketing and media group – RC Resolve is one of several new offerings we’re bringing to market in 2026, along with continued advances in AI-driven intelligence and delivery and our expanding global footprint.”

About RC Resolve

RC Resolve is Real Chemistry’s advisory practice for healthcare’s most critical business, regulatory and value inflection points where science, business, economics, policy and risk management intersect. RC Resolve combines insight, influence and decisive action to help organizations achieve desired outcomes and emerge stronger, more trusted and better prepared for what’s next.

About Real Chemistry: 25 Years of Future-Focused Healthcare

Celebrating its 25th anniversary this year, Real Chemistry is a tier-one partner to the world’s most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by our culture of innovation and creativity, Real Chemistry’s 2,000+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market and, most importantly, to the people who need them. Learn more at www.realchemistry.com.

Contacts

Media Contact:

media@realchemistry.com

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.0789
$0.0789$0.0789
+2.70%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Eric Trump on Tuesday described Bitcoin as a “modern-day gold,” calling it a liquid store of value that can act as a hedge to real estate and other assets. Related Reading: XRP’s Biggest Rally Yet? Analyst Projects $20+ In October 2025 According to reports, the remark came during a TV appearance on CNBC’s Squawk Box, tied to the launch of American Bitcoin, the mining and treasury firm he helped start. Company Holdings And Strategy Based on public filings and company summaries, American Bitcoin has accumulated 2,443 BTC on its balance sheet. That stash has been valued in the low hundreds of millions of dollars at recent spot prices. The firm mixes large-scale mining with the goal of holding Bitcoin as a strategic reserve, which it says will help it grow both production and asset holdings over time. Eric Trump’s comments were direct. He told viewers that institutions are treating Bitcoin more like a store of value than a fringe idea, and he warned firms that resist blockchain adoption. The tone was strong at times, and the line about Bitcoin being a modern equivalent of gold was used to frame American Bitcoin’s role as both miner and holder.   Eric Trump has said: bitcoin is modern-day gold — unusual_whales (@unusual_whales) September 16, 2025 How The Company Went Public American Bitcoin moved toward a public listing via an all-stock merger with Gryphon Digital Mining earlier this year, a deal that kept most of the original shareholders in control and positioned the new entity for a Nasdaq debut. Reports show that mining partner Hut 8 holds a large ownership stake, leaving the Trump family and other backers with a minority share. The listing brought fresh attention and capital to the firm as it began trading under the ticker ABTC. Market watchers say the firm’s public debut highlights two trends: mining companies are trying to grow by both producing and holding Bitcoin, and political ties are bringing more headlines to crypto firms. Some analysts point out that holding large amounts of Bitcoin on the balance sheet exposes a company to price swings, while supporters argue it aligns incentives between miners and investors. Related Reading: Ethereum Bulls Target $8,500 With Big Money Backing The Move – Details Reaction And Possible Risks Based on coverage of the launch, investors have reacted with both enthusiasm and caution. Supporters praise the prospect of a US-based miner that aims to be transparent and aggressive about building a reserve. Critics point to governance questions, possible conflicts tied to high-profile backers, and the usual risks of a volatile asset being held on corporate balance sheets. Eric Trump’s remark that Bitcoin has taken gold’s role in today’s world reflects both his belief in its value and American Bitcoin’s strategy of mining and holding. Whether that view sticks will depend on how investors and institutions respond in the months ahead. Featured image from Meta, chart from TradingView
Share
NewsBTC2025/09/18 06:00
NZD/USD holds losses below 0.5750 ahead of China trade data

NZD/USD holds losses below 0.5750 ahead of China trade data

The post NZD/USD holds losses below 0.5750 ahead of China trade data appeared on BitcoinEthereumNews.com. NZD/USD extends its losses for the second successive day
Share
BitcoinEthereumNews2026/01/14 09:54
Regulatory Heat and Investor Buzz: Chainlink and Hyperliquid Gain Momentum as BullZilla Leads the Best 1000x Crypto Presales in 2025

Regulatory Heat and Investor Buzz: Chainlink and Hyperliquid Gain Momentum as BullZilla Leads the Best 1000x Crypto Presales in 2025

Could a regulatory crackdown spark the next wave of growth for early-stage tokens? That’s the question traders are asking after New York’s Department of Financial Services (NYDFS) directed banks to implement advanced blockchain analytics to monitor digital asset activity. As traditional banks deepen their involvement in crypto, this move signals a new era of oversight [...] The post Regulatory Heat and Investor Buzz: Chainlink and Hyperliquid Gain Momentum as BullZilla Leads the Best 1000x Crypto Presales in 2025 appeared first on Blockonomi.
Share
Blockonomi2025/09/19 10:15